Safety Study of Human Neural Stem Cells Injections for Secondary Progressive Multiple Sclerosis Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

September 9, 2017

Primary Completion Date

May 29, 2021

Study Completion Date

May 29, 2021

Conditions
Secondary-progressive Multiple Sclerosis
Interventions
BIOLOGICAL

Human Neural Stem Cells

Allogenic human Neural Stem Cells (hNSCs) in four different dosages (5, 10, 16 or 24 millions). hNSCs are produced by the Laboratorio Cellule Staminali of Terni according to GMP guidelines and are obtained from brain specimens of several fetal human donors from spontaneous miscarriages occurred after the 8th week after conception.

Trial Locations (3)

6900

Neurocentro della Svizzera Italiana, Istituto di Neurosienze cliniche della svizzera italiana, Centro sclerosi Multipla, Lugano

71013

Casa Sollievo della Sofferenza - IRCCS, San Giovanni Rotondo

05100

Azienda Ospedaliera Santa Maria di Terni, Terni

All Listed Sponsors
collaborator

Associazione Revert ONLUS

UNKNOWN

collaborator

Neurocenter of Southern Switzerland

OTHER

collaborator

Fondazione Cellule Staminali

UNKNOWN

lead

Casa Sollievo della Sofferenza IRCCS

OTHER

NCT03282760 - Safety Study of Human Neural Stem Cells Injections for Secondary Progressive Multiple Sclerosis Patients | Biotech Hunter | Biotech Hunter